Enliven Therapeutics, Inc. (ELVN)
Largest Insider Buys in Sector
ELVN Stock Price History Chart
ELVN Stock Performance
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Insider Activity of Enliven Therapeutics, Inc.
Over the last 12 months, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $81.88M worth of Enliven Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $45.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Enliven Therapeutics, Inc.
| 2024-11-27 | Sale | CHIEF FINANCIAL OFFICER | 5,250 0.011% | $24.89 | $130,688 | -6.53% | ||
| 2024-10-28 | Sale | CHIEF FINANCIAL OFFICER | 6,250 0.015% | $28.56 | $178,485 | -13.08% | ||
| 2024-10-18 | Sale | CHIEF SCIENTIFIC OFFICER | 847 0.0021% | $30.00 | $25,413 | -12.36% | ||
| 2024-10-18 | Sale | PRESIDENT AND CEO | 924 0.0023% | $30.00 | $27,723 | -12.36% | ||
| 2024-10-18 | Sale | CHIEF OPERATING OFFICER | 716 0.0018% | $30.00 | $21,483 | -12.36% | ||
| 2024-10-18 | Sale | director | 1,570 0.004% | $30.00 | $47,104 | -12.36% | ||
| 2024-10-18 | Sale | CHIEF FINANCIAL OFFICER | 814 0.0021% | $30.00 | $24,422 | -12.36% | ||
| 2024-10-18 | Sale | CHIEF MEDICAL OFFICER | 816 0.0021% | $30.00 | $24,482 | -12.36% | ||
| 2024-10-15 | Sale | director | 1,270 0.003% | $27.67 | $35,143 | -8.59% | ||
| 2024-10-09 | Sale | CHIEF SCIENTIFIC OFFICER | 37,878 0.0895% | $28.16 | $1.07M | -7.20% | ||
| 2024-10-09 | Sale | PRESIDENT AND CEO | 16,710 0.0395% | $28.15 | $470,405 | -7.20% | ||
| 2024-10-08 | Sale | CHIEF SCIENTIFIC OFFICER | 13,267 0.0311% | $27.97 | $371,024 | -5.12% | ||
| 2024-10-08 | Sale | PRESIDENT AND CEO | 13,267 0.0311% | $27.96 | $370,929 | -5.12% | ||
| 2024-10-08 | Sale | director | 10,420 0.0246% | $28.17 | $293,557 | -5.12% | ||
| 2024-10-07 | Sale | CHIEF SCIENTIFIC OFFICER | 2,707 0.0063% | $27.61 | $74,727 | -1.75% | ||
| 2024-10-07 | Sale | PRESIDENT AND CEO | 2,730 0.0063% | $27.50 | $75,075 | -1.75% | ||
| 2024-10-07 | Sale | CHIEF FINANCIAL OFFICER | 1,270 0.0029% | $27.51 | $34,935 | -1.75% | ||
| 2024-10-04 | Sale | CHIEF SCIENTIFIC OFFICER | 7,522 0.0174% | $27.51 | $206,937 | -1.67% | ||
| 2024-10-04 | Sale | PRESIDENT AND CEO | 12,206 0.0282% | $27.51 | $335,792 | -1.67% | ||
| 2024-10-04 | Sale | director | 2,825 0.0065% | $27.51 | $77,704 | -1.67% |